Bioactivity | Onapristone is a progesterone receptor antagonist, with Kds of 11.6 nM and 11.90 nM for human endometrium and myometrium progesterone receptor in saturation analysis. Onapristone has antitumor activity[1][2]. |
Target | Kd: 1.6 nM (Human endometrium progesterone receptor), 11.90 nM (Human myometrium progesterone receptor) |
Invitro | Onapristone is a progesterone receptor antagonist, with Kds of 11.6 nM and 11.90 nM for human endometrium and myometrium progesterone receptor in saturation analysis. In Scatchard analysis, Onapristone shows Kds of 9.80 nM and 15.42 nM for human endometrium and myometrium progesterone receptor[1]. Onapristone (16, 64 μM) reduces the viability of ISHIKAWA cells after treatment for 96 h. Onapristone (20 μM) also induces ISHIKAWA cell apoptosis after treatment for 72 h. However, Onapristone shows no inhibition on HEC1A and SKUT2 cells[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Onapristone 相关抗体: |
CAS | 96346-61-1 |
Formula | C29H39NO3 |
Molar Mass | 449.62 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Puri CP, et al. Binding characteristics of progesterone and antiprogestin ZK 98.299 in human endometrial and myometrial cytosol. Biochim Biophys Acta. 1989 May 10;1011(2-3):176-82. [2]. Huang Y, et al. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 Feb;17(2):464-473. |